Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SYN-2510
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Instil Bio
Deal Size : $2,050.0 million
Deal Type : Licensing Agreement
Instil Bio and ImmuneOnco Announce License Agreement for IMM2510 and IMM27M Antibodies
Details : Instil is the in-licensing agreement with ImmuneOnc for ex-China development and commercial rights of ImmueOnco’s PD-L1xVEGF bispecific antibody, IMM2510 for the treating advanced solid tumors.
Product Name : IMM2510
Product Type : Large molecule
Upfront Cash : $50.0 million
August 01, 2024
Lead Product(s) : SYN-2510
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Instil Bio
Deal Size : $2,050.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?